Michael Drapcho, MD
Family Medicine · Hammond, LANPI 1316981475
Payments from drug & device makers
Across 127 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Impulse Dynamics (USA) Inc.$662
- Novo Nordisk$345
- Pfizer$198
- Merck$177
- AbbVie$154
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$144
- plus $838 from 18 others
What the payments were for
- Consulting fees$50020%
- Food & beverage$2,01880%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Impulse Dynamics (USA) Inc. | 2 | $662 |
| Novo Nordisk | 22 | $345 |
| Pfizer | 12 | $198 |
| Merck | 13 | $177 |
| AbbVie(2 entities) | 10 | $154 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $144 |
| GSK | 8 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $110 |
| Sanofi-aventis U.S. LLC | 7 | $94 |
| Lilly USA, LLC | 7 | $91 |
| Abbott | 4 | $86 |
| Novartis | 5 | $83 |
| AstraZeneca | 4 | $48 |
| E.r. Squibb & Sons, L.L.C. | 4 | $47 |
| Dexcom, Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,518 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 168 | $117,764 |
| MounjaroTirzepatide | 69 | $80,931 |
| LinzessLinaclotide | 88 | $67,916 |
| TrulicityDulaglutide | 48 | $48,092 |
| JanuviaSitagliptin Phosphate | 30 | $38,466 |
| TrintellixVortioxetine Hydrobromide | 37 | $28,766 |
| JardianceEmpagliflozin | 24 | $20,377 |
| MyrbetriqMirabegron | 44 | $20,230 |
| OzempicSemaglutide | 12 | $19,895 |
| FarxigaDapagliflozin Propanediol | 17 | $14,560 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $10,461 |
| GemtesaVibegron | 12 | $10,267 |
| EntrestoSacubitril/Valsartan | 12 | $8,374 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,846 |
| VerquvoVericiguat | 12 | $7,597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $91 | $129,023117 claims |
| PfizerEliquis | $198 | $117,764168 claims |
| AbbVieLinzess | $154 | $67,91688 claims |
| MerckJanuvia, Verquvo, Janumet | $177 | $52,53054 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $110 | $28,76637 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $12 | $25,71735 claims |
| Novo NordiskOzempic | $345 | $19,89512 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $128 | $18,30739 claims |
| AstraZenecaFarxiga | $48 | $14,56017 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $15 | $10,26712 claims |
| NovartisEntresto | $83 | $8,37412 claims |
| Johnson & JohnsonXarelto | $11 | $7,23412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Hammond
- Leonard TreanorHammond$29K
- Claude GilbreathHammond$15K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.